产品编号：GM-C05619
产品名称：ADCC FcγRIIIa(158V) Jurkat Effector Cell Line
目录价：询价
产品编号：GM-C05619
产品名称：ADCC FcγRIIIa(158V) Jurkat Effector Cell Line
目录价：询价
生长培养基：RPMI 1640+10%FBS+1%P.S+0.75μg/mL Puromycin+3.5μg/mL Blastincidin
细胞冻存液：FBS+10% DMSO
Assay Buffer：RPMI 1640+1% low IgG FBS+1% P.S
ADCC即抗体依赖性细胞介导的细胞毒作用(antibody dependent cell-mediated cytotoxicity, ADCC)，是指表达Fc受体的免疫细胞通过识别抗体的Fc段直接杀伤与抗体特异性结合的靶细胞的作用。现如今，ADCC作用机制被用来检测、评定抗体或靶细胞的功效。抗体与细胞表面上的目标抗原结合。如果抗体的Fc段同时结合到效应细胞(主要为自然杀伤细胞， natural killer cells)表面的FcγRIIIa受体上，两种类型的细胞即发生多重交联，导致ADCC作用机制通路的激活。 靶细胞的杀伤是此活化途径的终点，这一指标被用在经典的ADCC生物活性检测中，这些经典的检测方法利用供者的外周血单核细胞(PBMC)或自然杀伤(NK)细胞亚群作为效应细胞。这些细胞的应答变异性很大，难于制备，并容易引起很高的背景读数。
ADCC Reporter细胞系选择了ADCC作用机制通路激活过程中较早的事件作为检测的读出指标：即效应细胞中由NFAT(活化T细胞核因子)通路介导的基因转录的激活。此外，ADCC报告基因检测试剂盒使用工程改造的Jurkat细胞作为效应细胞，该细胞稳定表达了FcγRIIIa受体(高亲和158V)和由NFAT应答元件驱动表达的萤火虫萤光素酶。抗体在ADCC作用机制中的生物活性通过NFAT通路活化产生的萤光素酶定量，而效应细胞中的萤光素酶活性通过生物发光读数定量。检测的信号值高，且背景很低。
吉满生物依靠多年研究经验，利用巧妙的载体设计和第三代慢病毒报告基因系统，推出ADCC相关细胞系和ADCC活性检测服务，并可接受ADCC细胞系定制服务。
Guo C, Dai X, Du Y, Xiong X, Gui X. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunol Immunother. 2024 Aug 9;73(10):210. doi: 10.1007/s00262-024-03794-3. PMID: 39123089; PMCID: PMC11315865.
Shen A, Liu W, Wang H, Zeng X, Wang M, Zhang D, Zhao Q, Fang Q, Wang F, Cheng L, Shen G, Li Y. A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells. Am J Cancer Res. 2023 Jul 15;13(7):3246-3256. PMID: 37559991; PMCID: PMC10408481.
Zhang M, Zhang Y, Wu H, Wang X, Zheng H, Feng J, Wang J, Luo L, Xiao H, Qiao C, Li X, Zheng Y, Huang W, Wang Y, Wang Y, Shi Y, Feng J, Chen G. Functional characterization of AF-04, an afucosylated anti-MARV GP antibody. Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166964. doi: 10.1016/j.bbadis.2023.166964. Epub 2023 Nov 22. Erratum in: Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167046. doi: 10.1016/j.bbadis.2024.167046. PMID: 37995774.
Cheng LS, Zhu M, Gao Y, Liu WT, Yin W, Zhou P, Zhu Z, Niu L, Zeng X, Zhang D, Fang Q, Wang F, Zhao Q, Zhang Y, Shen G. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. Cell Mol Biol Lett. 2023 May 31;28(1):47. doi: 10.1186/s11658-023-00461-w. PMID: 37259060; PMCID: PMC10230818.
Yue J, Shao S, Zhou J, Luo W, Xu Y, Zhang Q, Jiang J, Zhu MM. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function. Invest New Drugs. 2024 Feb;42(1):106-115. doi: 10.1007/s10637-024-01417-3. Epub 2024 Jan 10. PMID: 38198061.
产品编号：GM-C05619
产品名称：ADCC FcγRIIIa(158V) Jurkat Effector Cell Line
目录价：询价
生长培养基：RPMI 1640+10%FBS+1%P.S+0.75μg/mL Puromycin+3.5μg/mL Blastincidin
细胞冻存液：FBS+10% DMSO
Assay Buffer：RPMI 1640+1% low IgG FBS+1% P.S
ADCC即抗体依赖性细胞介导的细胞毒作用(antibody dependent cell-mediated cytotoxicity, ADCC)，是指表达Fc受体的免疫细胞通过识别抗体的Fc段直接杀伤与抗体特异性结合的靶细胞的作用。现如今，ADCC作用机制被用来检测、评定抗体或靶细胞的功效。抗体与细胞表面上的目标抗原结合。如果抗体的Fc段同时结合到效应细胞(主要为自然杀伤细胞， natural killer cells)表面的FcγRIIIa受体上，两种类型的细胞即发生多重交联，导致ADCC作用机制通路的激活。 靶细胞的杀伤是此活化途径的终点，这一指标被用在经典的ADCC生物活性检测中，这些经典的检测方法利用供者的外周血单核细胞(PBMC)或自然杀伤(NK)细胞亚群作为效应细胞。这些细胞的应答变异性很大，难于制备，并容易引起很高的背景读数。
ADCC Reporter细胞系选择了ADCC作用机制通路激活过程中较早的事件作为检测的读出指标：即效应细胞中由NFAT(活化T细胞核因子)通路介导的基因转录的激活。此外，ADCC报告基因检测试剂盒使用工程改造的Jurkat细胞作为效应细胞，该细胞稳定表达了FcγRIIIa受体(高亲和158V)和由NFAT应答元件驱动表达的萤火虫萤光素酶。抗体在ADCC作用机制中的生物活性通过NFAT通路活化产生的萤光素酶定量，而效应细胞中的萤光素酶活性通过生物发光读数定量。检测的信号值高，且背景很低。
吉满生物依靠多年研究经验，利用巧妙的载体设计和第三代慢病毒报告基因系统，推出ADCC相关细胞系和ADCC活性检测服务，并可接受ADCC细胞系定制服务。
Guo C, Dai X, Du Y, Xiong X, Gui X. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunol Immunother. 2024 Aug 9;73(10):210. doi: 10.1007/s00262-024-03794-3. PMID: 39123089; PMCID: PMC11315865.
Shen A, Liu W, Wang H, Zeng X, Wang M, Zhang D, Zhao Q, Fang Q, Wang F, Cheng L, Shen G, Li Y. A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells. Am J Cancer Res. 2023 Jul 15;13(7):3246-3256. PMID: 37559991; PMCID: PMC10408481.
Zhang M, Zhang Y, Wu H, Wang X, Zheng H, Feng J, Wang J, Luo L, Xiao H, Qiao C, Li X, Zheng Y, Huang W, Wang Y, Wang Y, Shi Y, Feng J, Chen G. Functional characterization of AF-04, an afucosylated anti-MARV GP antibody. Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166964. doi: 10.1016/j.bbadis.2023.166964. Epub 2023 Nov 22. Erratum in: Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167046. doi: 10.1016/j.bbadis.2024.167046. PMID: 37995774.
Cheng LS, Zhu M, Gao Y, Liu WT, Yin W, Zhou P, Zhu Z, Niu L, Zeng X, Zhang D, Fang Q, Wang F, Zhao Q, Zhang Y, Shen G. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. Cell Mol Biol Lett. 2023 May 31;28(1):47. doi: 10.1186/s11658-023-00461-w. PMID: 37259060; PMCID: PMC10230818.
Yue J, Shao S, Zhou J, Luo W, Xu Y, Zhang Q, Jiang J, Zhu MM. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function. Invest New Drugs. 2024 Feb;42(1):106-115. doi: 10.1007/s10637-024-01417-3. Epub 2024 Jan 10. PMID: 38198061.
